左卡尼汀治疗非酒精性脂肪肝79例临床观察分析

Evaluation of the clinical efficacy and safety of levocarnitine in the treatment of nonalcoholic fatty liver

目的:观察左卡尼汀治疗非酒精性脂肪肝的效果。方法:79人被随机分入左卡尼汀组(应用左卡尼汀治疗4周,减量后继续治疗4周),而78人以非诺贝特片剂口服治疗作为对照组。结果:应用左卡尼汀治疗非酒精性脂肪肝79例,显效64例(81.0%),有效9例(11.4%),总有效率为92.4%,无效6例(7.6%),效果明显优于非诺贝特。结论:左卡尼汀治疗非酒精性脂肪肝有一定效果,且不良反应低,值得推广。

Objective：To evaluate the clinical efficacy of levocarnitine on nonalcoholic fatty liver （NAFL）. Methods ： 157 cases were randomly assigned 79 pts with NAFL to receive levocarnitine （ cures 4 weeks, then re-duce the quantity for subsequent 4 weeks）, and 78 pts to receive the fenofibrate tablets as treatment group. Re-suits： Among all the patients, there were 64 cases markedly improved （81.0%）, 9 cases partial improved （ 11.4% ） and 6 cases ineffective. The total effictive rate was 92. 4%. The therapeutic effect of levocarnitine for NAFL is significantly better than that of fenofibrate. Conclusions： Levocarnitine have a significant therapeutic effect on the treatment of NAFL with lower side effect and higher safety.